- Home
- CVV vs EQ Comparison
CVV vs EQ Comparison
Compare CVV & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVV
- EQ
- Stock Information
- Founded
- CVV 1982
- EQ 2017
- Country
- CVV United States
- EQ United States
- Employees
- CVV N/A
- EQ N/A
- Industry
- CVV Industrial Machinery/Components
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- CVV Technology
- EQ Health Care
- Exchange
- CVV Nasdaq
- EQ Nasdaq
- Market Cap
- CVV 25.5M
- EQ 24.8M
- IPO Year
- CVV N/A
- EQ 2018
- Fundamental
- Price
- CVV $3.60
- EQ $0.63
- Analyst Decision
- CVV
- EQ Buy
- Analyst Count
- CVV 0
- EQ 2
- Target Price
- CVV N/A
- EQ $5.00
- AVG Volume (30 Days)
- CVV 43.5K
- EQ 130.9K
- Earning Date
- CVV 11-13-2024
- EQ 11-13-2024
- Dividend Yield
- CVV N/A
- EQ N/A
- EPS Growth
- CVV N/A
- EQ N/A
- EPS
- CVV N/A
- EQ N/A
- Revenue
- CVV $23,573,000.00
- EQ $45,914,000.00
- Revenue This Year
- CVV N/A
- EQ $4.76
- Revenue Next Year
- CVV N/A
- EQ N/A
- P/E Ratio
- CVV N/A
- EQ N/A
- Revenue Growth
- CVV N/A
- EQ 7.70
- 52 Week Low
- CVV $2.70
- EQ $0.49
- 52 Week High
- CVV $6.35
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- CVV 44.36
- EQ 37.33
- Support Level
- CVV $3.63
- EQ $0.49
- Resistance Level
- CVV $3.87
- EQ $0.73
- Average True Range (ATR)
- CVV 0.33
- EQ 0.08
- MACD
- CVV -0.09
- EQ -0.01
- Stochastic Oscillator
- CVV 9.09
- EQ 38.92
About CVV CVD Equipment Corporation
CVD Equipment Corp is engaged in the manufacturing of chemical vapor deposition equipment, customized gas control systems, the manufacturing of process equipment suitable for the synthesis of a variety of one-dimensional nanostructures and nanomaterials and a line of furnaces, all of which are used to produce semiconductors and other electronic components. The company operates through the segments of CVD Equipment, CVD materials, and Stainless Design Concepts. It generates maximum revenue from the CVD Equipment segment. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport, and similar equipment.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.